Date of Award


Document Type




First Advisor

Zhiwen Zhang


Cancer is a devastating disease which affects millions. For this reason, many scientists are working to develop drugs that can specifically target cancer cells within the body. Preclinical trials are an important phase in the drug development process, as they allow scientists to determine whether or not a drug candidate may be viable for human use. Targeted therapies can be achieved by using monoclonal antibodies as well as small molecule drugs. In this study we compared the effects of two control monoclonal antibody drugs, “mAb1” and “mAb2,” with one small molecule drug, “Drug S,” on the MDAMB231 human breast cancer cell line in a xenograft SCID mouse model. All treatment groups containing Drug S exhibited the same trends as the negative control, mAb1, suggesting Drug S is an ineffective tumorreducing treatment.